Oral and Sublingual Ketamine

A Comparative Analysis of the Pharmacokinetics of Oral and Sublingual Ketamine as Adjunctive Therapies in Major Depressive Disorder

Major Depressive Disorder (MDD) is one of the most common and severe mental illnesses in the world. Ketamine treatment, especially intravenous ketamine (IVK) and intranasal esketamine (INE), is becoming more popular and is being used more. But these ways of administering aren't perfect. They mostly have problems with cost, accessibility, and the issues of administering. The oral and sublingual routes of ketamine are cheaper alternatives, but they haven't been looked into as much in the medical and academic circles. This is a small pilot feasibility study, involving ten patient participants who will be randomly assigned to take ketamine by oral and sublingual routes as part of a single-blind, crossover design. A local London pharmacy-Ultimate Care Compounding will provide the ketamine formulations.

Ten patients between 18 and 65 years old with Major Depressive Disorder will be recruited from the Mental Health Care Programs at LHSC, Victoria Hospital and SJHC, Parkwood Institute, (that has treatment resistant depression treatment focus). After a screening baseline visit, which will include clinical interviews with medication reconciliation, psychiatric evaluations, routine standard laboratory tests, and an electrocardiogram (ECG).

Due to capacity limitations at the Centre for Clinical Investigation and Therapeutics (CCIT), a maximum of 5 participants will undergo pharmacokinetic sampling simultaneously, enrolment will proceed in two sequential groups with treatment order assigned by group. Group A (n=5): The first 5 eligible participants will receive oral ketamine in Treatment Period 1 and sublingual ketamine in Treatment Period 2. Group B (n=5): The next 5 eligible participants will receive sublingual ketamine in Treatment Period 1 and oral ketamine in Treatment Period 2. Recruitment for Group B will commence once Group A has completed the clinical intervention phase.

During Monday and Thursday of each of Weeks 1 and 2, Group A will receive oral ketamine, while Group B will receive sublingual ketamine. Weeks 3 and 4 are a washout period. In Weeks 5 and 6, on Mondays and Thursdays, groups will switch to the other form of administration [See flowchart of study procedure]. Weeks 7 and 8 are washout periods to ensure consistency with the first half of the study and provide a similar framework for clinical assessments. Blood samples will be collected at 2 time points at the Center for Clinical Investigation and Therapeutics at University Hospital. The study goal is to help define safe and effective oral/SL ketamine doses based on Pharmacokinetic profiles.

Study Overview

• Status: Not yet recruiting
• Conditions: Major Depression Severe
• Intervention / Treatment: Drug: 75 mg of oral ketamine; Drug: Sublingual ketamine 75 mg

Detailed Description

Background and Rationale:

1.1 Introduction Major Depressive Disorder (MDD) represents one of the most prevalent and debilitating psychiatric disorders, with the WHO stating that it is the most disabling illness worldwide, affecting over 300 million people. Current pharmacotherapies, although effective for some, often fail to provide rapid and lasting relief for many patients, with remission rates of 67% and treatment-resistant depression occurring in approximately 30% of those diagnosed with MDD.

Ketamine has been shown to improve symptoms of treatment-resistant major depressive disorder. The increasing acceptance and use of ketamine, specifically intravenous ketamine (IVK) and intranasal esketamine (INE), have shown promise in bridging this therapeutic gap, particularly given its rapid onset of action.

However, these routes of administration are not without their challenges.

1. These challenges include the high cost of IVK and INE preparations compared to oral ketamine. The cost of a single session with IVK can be $400 to $800 CAD due to fees for hospital room and staff. The cost of a single dose of INE is $600 to $1000, not including any hospital costs. On the other hand, the cost of a single dose of compounded oral ketamine (75 mg) is only $5 to $15 CAD.
2. The second issue is accessibility. Patients have to be admitted to hospital for IVK administration. Hence, this is done in specialised urban centres, a disadvantage for rural residents.
3. The third is administration logistics, like arranging the time of clinical staff to do the IVK and INE treatment.
4. Lastly, INE and IVK carry a higher burden of common adverse effects of ketamine, with more dissociation and hypertension occurring compared to oral dosing.

1.2 Current Landscape of Ketamine Administration: While IVK offers rapid antidepressant effects, its administration demands specialised facilities, anaesthesiologists, and nursing staff, leading to heightened costs. INE, though more accessible, still incurs significant costs per dose in the US, raising questions regarding its cost-effectiveness. These challenges highlight an urgent need for more affordable and easily administrable ketamine alternatives.

1.3 The Case for Oral and Sublingual Ketamine: Oral and sublingual (SL) routes of ketamine present, as such, alternative and affordable methods of treatment but have been relatively under-explored in the academic and medical communities. Patients in Ontario have access to oral ketamine therapy; however, this is mostly through private clinics, and it is not covered by OHIP. Preliminary research indicates oral ketamine's efficacy in treating MDD or suicidality; however, the quality of previous studies varies.

Oral ketamine studies Appendix A provides a summary of the studies available on oral ketamine in MDD, which detail the significant variation in doses and frequency of administration. For example, the dose of oral ketamine in these studies varies between 0.5 and 7 mg/kg. The frequency of medication administration is from once or twice a week to once a month. A few review papers that summarise these findings on oral ketamine in MDD have also been published, which also indicate the variability in dose and frequency of oral ketamine.

Sub-lingual ketamine studies When we reviewed SL ketamine for depression (in April 2025), there were very few studies that investigated sublingual ketamine. The earliest study of SL ketamine was in refractory unipolar and bipolar depression. This study investigated very low-dose sublingual ketamine in refractory unipolar and bipolar depression. They observed a rapid onset of action with good tolerability. After that, there was a gap in terms of studies and publications on sublingual ketamine in depression. The most recent studies on SL ketamine in MDD were published by Hull et al. 2022 and Liester et al. 2024. They also observed effective reduction in symptoms of depression and anxiety with sublingual ketamine. Hence, there are very few studies on SL ketamine in MDD.

Lack of use of pharmacokinetic profiles in previous studies

1.4 Absence of consistency in dosing Oral and SL Ketamine for MDD: A major gap in the current literature in this area is the significant variability in dosage, administration frequency, and rationale behind dosing decisions. The dose of oral ketamine varied between 0.5 and 7 mg/kg. The frequency of administration varies from daily to weekly. While it's understood that oral ketamine undergoes significant metabolism (approximately 80%), resulting in variable bioavailability ranging from 10% to 20%, there exists no standardised dosing protocol. This inconsistency in dosing, coupled with the lack of clear rationale for dose determination in clinical trials, underscores the pressing need for a standardised protocol.

1.5 Need for this study - can pharmacokinetics help improve Oral and SL Ketamine dose determination in MDD? The pharmacokinetics (PK) of oral and sublingual (SL) ketamine are relatively well characterised in the context of anaesthesia; however, their PK profiles in the treatment of major depressive disorder (MDD) remain insufficiently studied. This is a critical gap: ketamine's antidepressant effects may depend not only on the parent drug but also on metabolites, particularly norketamine and hydroxynorketamine, which have demonstrated antidepressant properties in preclinical models. Without PK data linking plasma concentrations to clinical response, rational dose selection is impossible.

Sublingual administration theoretically offers pharmacokinetic advantages: by bypassing hepatic first-pass metabolism, it may achieve higher and more consistent plasma concentrations at equivalent doses. However, whether these theoretical benefits translate into improved clinical outcomes in MDD is unknown-no study has directly compared oral versus sublingual ketamine PK profiles within the same patients

Comparison of oral and sublingual ketamine ORAL Bioavailability - 10-20% First-pass metabolism - High Peak plasma concentration - Low Antidepressant onset - 2-4 hours Tolerability - Mild SUBLINGUAL Bioavailability - 20-30% First-pass metabolism - Comparatively less Peak plasma concentration - Moderate Antidepressant onset - 1-3 hours Tolerability - Mild to moderate

Why Current Dosing Is Problematic

Published studies of oral and sublingual ketamine for depression report doses ranging from 0.5 to 7 mg/kg, selected empirically rather than based on target plasma concentrations. This approach has three consequences:

1. Unexplained response variability - Patients who fail to respond may have inadequate drug exposure rather than true treatment resistance. Without PK data, these scenarios cannot be distinguished.
2. Lack of clarity on dose-response relationship - The optimal plasma concentration for antidepressant effect is unknown. Higher doses increase adverse effects; lower doses may be subtherapeutic. PK data are required to identify the therapeutic window.
3. No basis for route selection - Clinicians cannot determine whether oral or sublingual administration is preferable for a given patient because comparative PK data do not exist in MDD.

How This Study Will Address the Gap This pilot study will characterise the pharmacokinetic profiles of oral and sublingual ketamine (75 mg) in patients with MDD using a crossover design in which each participant serves as their own control. Plasma concentrations of ketamine and norketamine will be measured at multiple timepoints to determine Cmax, Tmax, and AUC for each route.

The resulting data will:

• Establish whether sublingual administration achieves higher bioavailability than oral administration in MDD patients
• Quantify within-subject and between-subject variability in PK parameters
• Provide preliminary data on the relationship between plasma concentrations and clinical response
• Inform evidence-based dose selection for future efficacy trials

This study represents a necessary first step towards standardised, pharmacologically rational dosing of oral and sublingual ketamine for depression.

Research Question(s) and Objectives/Hypotheses:

2.1 Research Questions: How do the pharmacokinetic (PK) profiles of oral and sublingual ketamine differ in individuals diagnosed with major depressive disorder? Do PK parameters of oral and SL ketamine correlate to changes in depressive symptoms? 2.2 Primary Objective: To delineate and compare the pharmacokinetic profiles of oral and sublingual administration of ketamine, including serum ketamine and norketamine levels, in a cohort of individuals diagnosed with major depressive disorder.

2.3 Primary Hypothesis: There will be distinct differences in the pharmacokinetic parameters, specifically AUC(0-8), Cmax, and Tmax, between oral and sublingual administration of ketamine in individuals diagnosed with major depressive disorder.

2.4 Exploratory Objective/Hypothesis: To explore potential correlations between specific PK parameters, including serum ketamine and norketamine levels, of oral and sublingual ketamine and therapeutic response and improvement in depressive symptoms. We will use depressive symptom ratings with the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Aspberg Depression Rating Scale (MADRS). Preliminary evidence might suggest that specific PK parameters could be associated with clinical improvements based on a trending reduction on both HAMD & MADRS.

• Study Type: Interventional
• Enrollment (Estimated): 10
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Rohit Lodhi, MD; Phone Number: +1-519-646-6100; Email: rlodhi2@uwo.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants must meet all the following criteria to be eligible for the study. Appendix B is a checklist that will be used by Dr. Hammound for screening, based on the following inclusion and exclusion criteria.

  1. Age: Between 18 and 65 years (inclusive) at the time of screening.
  2. Weight: Equal to or greater than 50 kg (110 lbs).
  3. Diagnosis: A current diagnosis of Major Depressive Disorder (MDD), moderate to severe in intensity, as defined by the DSM-5 criteria.
  4. Current Episode: Experiencing a moderate to severe Major Depressive Episode (MDE) at screening.
  5. Ongoing Treatment: Actively receiving pharmacological treatment for MDD at the time of enrollment.
  6. Treatment Resistance: Documented history of inadequate response to at least two antidepressant medications, each from a different pharmacological class, administered at an adequate dose and duration.
  7. Capacity and Consent: Able and willing to provide written informed consent after understanding the nature, risks, and potential benefits of the study.
  8. Clinical Oversight: Currently under the regular care of a psychiatrist or general practitioner (GP).
  9. Support System: Has a responsible adult (e.g., family member or caregiver) who can accompany them from study visits or ensure safe transportation after ketamine has been used.
  10. Able to speak, read and understand English

Exclusion Criteria:

• Participants will be excluded if any of the following criteria apply:

  1. Suicidality: Active suicidal ideation with plan or intent, or suicidal behavior, within the past 3 months.
  2. Concomitant Medications: Use of medications that may pose a risk of respiratory depression or serious adverse events when combined with ketamine (e.g., benzodiazepines, opioids, barbiturates).
  3. Medical Comorbidities: Presence or history of significant or unstable medical conditions that could interfere with study participation or pose a safety risk, including but not limited to cerebrovascular accident, cardiac decompensation, large vessel aneurysms, glaucoma etc.. Participants with clinically significant laboratory abnormalities, as determined by the investigator, will also be excluded.
  4. Hypersensitvity to ketamine
  5. Uncontrolled hypertension (blood pressure ≥140/90 mmHg at screening, which may be repeated after 30 minutes rest)
  6. Psychiatric Comorbidities: Diagnosis of bipolar disorder, psychotic disorders, or history of psychotic symptoms.
  7. Substance Use: Clinically significant alcohol or substance use disorder within the last 6 months, as defined by DSM-5 criteria.
  8. Cognitive Impairment: Any condition resulting in impaired capacity to understand or consent to participation or to comply with study procedures.
  9. Pregnancy and Lactation: Pregnant or breastfeeding individuals.
  10. Concurrent Research Participation: Participation in another interventional clinical trial or use of an investigational drug within the 30 days prior to screening.
  11. Current or recent (within 90 days) treatment with ketamine (oral, IV or intranasal).
  12. ECG demonstrates abnormalities like Qtc interval>470 ms or any arrhythmia reported as clinically significant or abnormal by the interpreting physician. Exclusionary findings would include uncontrolled atrial fibrillation, ventricular arrhythmias, heart block, or other abnormalities that could pose a safety risk with ketamine administration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: First part of the study; Five patients will receive 75 mg of oral ketamine in weeks 1-2, weeks 3-4 are washout and weeks 5-6 they will crossover to receive 75 mg of sublingual keatmaine.	Drug: 75 mg of oral ketamine; Ketamine in the oral preperation or form; Drug: Sublingual ketamine 75 mg; Sublingual preparation of ketamine
Experimental: Second part of the study; Five patients will receive 75 mg of sublingual ketamine in weeks 1-2, weeks 3-4 are washout and weeks 5-6 they will crossover to receive 75 mg of oral keatmaine.	Drug: 75 mg of oral ketamine; Ketamine in the oral preperation or form; Drug: Sublingual ketamine 75 mg; Sublingual preparation of ketamine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic measures	Plasma concentration of ketamine Plasma concentration of norketmaine Area Under Curve from 0 to 8 hours Area Under Curve from 8 hours to infinity Half-life of the log-linear phase Cmax (i.e. peak plasma drug concentration) Tmax (i.e. the time taken to reach the maximum concentration).	Plasma samples will be collected at 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, and 8 hours of the first day of weeks 1 and 5.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montgomery-Aspberg Depression Rating Scale (MADRS).	This is a clinician administered 10 item scale for severity of major depressive disorder. Scores range between 0 to 60 and higher scores indicate more severity. 0-6: is Normal or Remission 7-19: Mild Depression 20-34: Moderate Depression 35-60: Severe Depression	This scale will be used at screening and then: Week 1 and Week 2 - biweekly Week 3 and 4 - once a week Week 5 and 6 - biweekly Week 7 and 8 - once a week
Hamilton Depression Rating Scale (HAM-D17)	This is a clinician administered scale for measurement of severity of major depressive disorder. This 17 item Hamilton Depression Rating Scale where the scores will vary between 0 to 52, with higher score meaning worse outcomes. No depression or remission score: 0 to 7; mild depression score: 8 to 16; moderate depression score: 17 to 23 and severe depression score is at or above 24. We are not looking at specific scores as outcomes, trend in scores will be evalauted.	This scale will be used at screening and then: Week 1 and Week 2 - biweekly Week 3 and 4 - once a week Week 5 and 6 - biweekly Week 7 and 8 - once a week

Collaborators and Investigators

• Sponsor: Western University, Canada

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): October 1, 2027

Study Registration Dates

• First Submitted: May 23, 2026
• First Submitted That Met QC Criteria: June 28, 2026
• First Posted (Actual): July 6, 2026

Study Record Updates

• Last Update Posted (Actual): July 6, 2026
• Last Update Submitted That Met QC Criteria: June 28, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Depression; ketamine
• Additional Relevant MeSH Terms: Behavioral Symptoms; Behavior; Depression; Organic Chemicals; Hydrocarbons; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Ketamine
• Other Study ID Numbers: 127065

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This requires additional consultation after which we may decide to share the data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No